Format

Send to

Choose Destination
Int J Mol Sci. 2019 Sep 19;20(18). pii: E4637. doi: 10.3390/ijms20184637.

Klotho: A Major Shareholder in Vascular Aging Enterprises.

Author information

1
Division of Nephrology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. kjlim@mgh.harvard.edu.
2
MGH Renal Associates, 165 Cambridge Street, Suite 302, Boston, MA 02114, USA. kjlim@mgh.harvard.edu.
3
Renal Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02114, USA. arv.halim@gmail.com.
4
Renal Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02114, USA.
5
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (UCSF), 1450 3rd St, San Francisco, CA 94158, USA. Alan.Ashworth@ucsf.edu.
6
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UK. Irene.Chong@icr.ac.uk.

Abstract

Accelerated vascular aging is a condition that occurs as a complication of several highly prevalent inflammatory conditions such as chronic kidney disease, cancer, HIV infection and diabetes. Age-associated vascular alterations underlie a continuum of expression toward clinically overt cardiovascular disease. This has contributed to the striking epidemiologic transition whereby such noncommunicable diseases have taken center stage as modern-day global epidemics and public health problems. The identification of α-Klotho, a remarkable protein that confers powerful anti-aging properties has stimulated significant interest. In fact, emerging data have provided fundamental rationale for Klotho-based therapeutic intervention for vascular diseases and multiple other potential indications. However, the application of such discoveries in Klotho research remains fragmented due to significant gaps in our molecular understanding of Klotho biology, as well as hurdles in clinical research and experimental barriers that must first be overcome. These advances will be critical to establish the scientific platform from which future Klotho-based interventional trials and therapeutic enterprises can be successfully launched.

KEYWORDS:

Klotho; arteriosclerosis; chronic kidney disease (CKD), cancer; diabetes; vascular aging; vascular calcification

PMID:
31546756
DOI:
10.3390/ijms20184637
Free full text

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI)
Loading ...
Support Center